Dirk Schnappinger, PhD

Highlights

1
Nature microbiology · 2025
SESabine Ehrt DSDirk Schnappinger
PMID: 39794471PMCID: PMC11790485DOI eCommonsSenior author19 citations
2
mBio · 2023
SESabine Ehrt KYKyu Y. Rhee DSDirk Schnappinger
PMID: 37350592PMCID: PMC10470730DOISenior author14 citations
3
Nature communications · 2024
SWSae Woong Park SESabine Ehrt DSDirk Schnappinger
PMID: 38755122PMCID: PMC11099021DOISenior author10 citations

Publications

162

Funding

44 View NIH portfolio on RePORTER ↗

Active

14 grants

Co-I
Determinants of TB Control, Relapse, and Reinfection
National Institute of Allergy and Infectious Diseases · 2026–2031
P01AI202868-06
MPI
Microbiology of Treatment Shortening in Tuberculosis
National Institute of Allergy and Infectious Diseases · 2026–2031
P01AI181935-01A1
Co-I
Mechanisms and Consequences of Clinical Pressure on Pathways in Mtb
National Institute of Allergy and Infectious Diseases · 2020–2031· 2 renewals
P01AI143575-06
PI
Mechanism of action analyses for TBDA hit and lead compounds
Bill & Melinda Gates Foundation · 2026–2029
INV-100451
PI
TB gene modulation to build shorter drug regimens
Bill & Melinda Gates Foundation · 2026–2029
INV-100452
MPI
Understanding resistance and tolerance to nitroimidazoles in Mycobacterium tuberculosis
National Institute of Allergy and Infectious Diseases · 2025–2029
R01AI192524-01
Sub-PI
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
National Institute of Allergy and Infectious Diseases · 2024–2029 · via University of California, San Francisco
UM1AI179699-02
Co-I
Pulmonary TB-CHIM Programme
Wellcome Trust · 2025–2028 · via Harvard University
WC-206057-206058
MPI
M. tuberculosis carbon metabolism during infection
National Institute of Allergy and Infectious Diseases · 2023–2028
R01AI177560-01
MPI
Conditional M. tuberculosis knockdown mutants in mice with human-like pathology
National Institute of Allergy and Infectious Diseases · 2026–2028
R21AI190768-01A1
PI
Gene inactivation and modulation of Mtb targets to build combinations
Bill & Melinda Gates Foundation · 2023–2026
BMGF INV-055894
PI
Conditional Mtb knockdown mutants for TB drug discovery
Bill & Melinda Gates Foundation · 2023–2026
BMGF INV-055896
Sub-PI
Chemical Genomics of Tuberculosis
Bill & Melinda Gates Foundation · 2022–2026 · via Broad Institute Inc
BI 230987-03
Co-I
Determinants of TB control, relapse and reinfection
National Institute of Allergy and Infectious Diseases · 2021–2026
U19AI162568-01

Completed grants (30)

Sub-PI
Development of a comprehensive RNAseq database of hypomorphs for small molecule target Identification against Mycobacterium tuberculosis
Bill & Melinda Gates Foundation · 2023–2025 · via Broad Institute Inc
BI 240369-02
Co-I
Conditional Expression of Mycobacterial Genes
National Institute of Allergy and Infectious Diseases · 2012–2024· 2 renewals
R01AI063446-15
KP
Conditionally Replicating Mycobacterium Tuberculosis Vaccines
National Institute of Allergy and Infectious Diseases · 2018–2024
R01AI135629-04
PI
BMGF-funded collaboration with Adapsyn
Adapsyn Bioscience Inc · 2023–2024Contract
ABI 227672-01
MPI
Development of a self inactivating, highly effective TB vaccine
National Institute of Allergy and Infectious Diseases · 2019–2024 · via University of Pittsburgh
R01AI143788-05
Sub-PI
Targeting Biotin Metabolism in Mycobacterium Tuberculosis
National Institute of Allergy and Infectious Diseases · 2019–2023 · via Regents of the University of Minnesota
R01AI143784-05
PI
2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar
NIAID · 2023–2023 · via NIH RePORTER
R13AI176609-01
PI
Conditional M. tuberculosis knockdown mutants for TB drug discovery (INV-004761)
Bill & Melinda Gates Foundation · 2020–2023
BMGF 210849-03
PI
Partial gene inactivation and pharmacological modulation of Mtb targets (INV-004764)
Bill & Melinda Gates Foundation · 2020–2023
INV-004764
Sub-PI
Siderophore Inhibitors for Tuberculosis that Block Mycobactin Biosynthesis
National Institute of Allergy and Infectious Diseases · 2018–2023 · via Regents of the University of Minnesota
R01AI136445-05
Sub-PI
Characterization of the nutrient assimilation pathways in M. tuberculosis
National Institute of Allergy and Infectious Diseases · 2020–2022 · via Cornell University - Ithaca
R01AI150916-02
Co-I
Chemigenomic Drug Discovery for Tuberculosis
U.S. Department of Defense · 2017–2022 · via Harvard University
W81XWH-17-PRMRP-FPA
Sub-PI
Chemical Genomics of Tuberculosis
Bill & Melinda Gates Foundation · 2018–2022 · via Broad Institute Inc
OPP 1207840
Sub-PI
Controlled Human Infection Model: detection of vaccine effect in NHPs
Bill & Melinda Gates Foundation · 2017–2021 · via Harvard University
OPP1180610
PI
Vulnerability of M. Tuberculosis to Partial Gene Inactivation
Bill & Melinda Gates Foundation · 2017–2021
BMGF INV-009731
KP
Tri-Institutional TB Research Unit: Persistence and Latency
National Institute of Allergy and Infectious Diseases · 2014–2021· 2 renewals
U19AI111143-05
Sub-PI
A Dynamic Drug Delivery System (D3S) to Accelerate the Profiling of Early Discovery Compounds
Bill & Melinda Gates Foundation · 2019–2020 · via Hackensack Meridian Health Inc
OPP1154895
PI
Amendment 1 to Consulting Agreement (202456)
Guinn Management · 2019–2020Contract
GM 202576-01
PI
Consulting Agreement with Kristine Guinn
Guinn Management · 2019–2020Contract
GM 202456-01
PI
Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
Bill & Melinda Gates Foundation · 2017–2020
BMGF OPP1024065
Sub-PI
A Dynamic Drug Delivery System (D3S) to Accelerate the Profiling of Early Discovery Compounds
Bill & Melinda Gates Foundation · 2016–2019 · via Rutgers, The State University of New Jersey – New Brunswick
OPP1154895
Sub-PI
Conditionally Replicating Strains of BCG
National Cancer Institute · 2018–2019 · via Harvard T. H. Chan School of Public Health
HHSN2612015000031
MPI
Decoding the Roles of Critical Genes of Unknown Function in M. tuberculosis
National Institute of Allergy and Infectious Diseases · 2013–2019 · via Harvard University
U19AI107774-05
PI
Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development
Bill & Melinda Gates Foundation · 2010–2018
OPP1024065 EWOF
Sub-PI
Comprehensive Chemigenomic Approach to Tuberculosis (CCAT)
Bill & Melinda Gates Foundation · 2014–2018 · via Broad Institute Inc
OPP1084233
Sub-PI
Mycobacterial Strain Development for Human Challenge
Bill & Melinda Gates Foundation · 2016–2017 · via Harvard University
OPP1135516
PI
Biotin Synthesis and Biotin Ligation in Mtb
National Institute of Allergy and Infectious Diseases · 2010–2016
R01AI091790-05 EW
KP
pH Homeostasis in Mycobacterium Tuberculosis
National Institute of Allergy and Infectious Diseases · 2009–2014
R01AI081725-05
PI
Robust Genetic Switches for Mycobacteria
NIAID · 2011–2012 · via NIH RePORTER
R56AI089911-01A1
PI
Alternative Respiratory Chains of M. tuberculosis
NIAID · 2004–2010 · via NIH RePORTER
R01AI057443-04

Available technologies

1 View full WCM portfolio ↗

Conditionally Replicating M. bovis for Treating Bladder Cancer and Tuberculosis
PCT filedPoC Data
9126

News mentions

6 View all WCM news ↗

Weill Cornell Medicine Awarded Grant to Shorten TB Treatment Regimen
September 17, 2026
Researchers at Weill Cornell Medicine have received a $17.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases to discover new approaches to shorten tuberculosis (TB) treatment, potentially making it easier for patients to complete therapy.
Dr. Sabine Ehrt Named Chair of the Department of Microbiology and Immunology at Weill Cornell Medicine
April 14, 2025
As chair, Dr. Ehrt seeks to build on the department’s already robust national and international footprint in tuberculosis research and expand its portfolio in other areas of research and innovation.
Designing Self-Destructing Bacteria to Make Effective Tuberculosis Vaccines
February 25, 2025
Working toward more effective tuberculosis (TB) vaccines, researchers have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the bacteria after they activate an immune response.
NIH Funds Consortium to Accelerate Development of New TB Treatments
July 8, 2024
A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).
Weill Cornell Medicine Receives Grants for Tuberculosis Drug Development
December 21, 2023
Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis (TB) drug development.

Show 1 more mention

CinA Protein Contributes to Drug Tolerance in Mycobacterium tuberculosis
May 4, 2022
Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.

Media highlights

Weill Cornell Receives $17.4 Million Grant To Pursue Shorter Tuberculosis Treatment
FingerLakes1.com · September 18, 2026

Mentoring

5 All publications with mentees →

KO
Kathryn O'Brien
Cell & Developmental Biology (PhD) · Class of 2015
- Mycobacterium tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in Antioxidant Defense.
  PLoS pathogens · 2016
- Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis.
  PLoS pathogens · 2014
- A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.
  Proceedings of the National Academy of Sciences of the United States of America · 2013
View all 3 →
EK
Eonmin Ko
Postdoc mentee · since 2024
PT
Prajna Tripathi
Postdoc mentee · since 2021
JR
Jessica Rose Willdigg
Postdoc mentee · 2023–2026
UM
Usama Mukhtar
Biochemistry, Cell & Molecular Biology (PhD) · Class of 2017